Open Access Article
Bimod
Thapa
a,
Farideh
Javid
b,
Cameron
Lawson
a,
Mark
Soesanto†
c and
Karl
Hemming
*a
aDivision of Chemistry and Chemical Engineering, University of Huddersfield, Queensgate, Huddersfield, HD1 3DH, UK. E-mail: k.hemming@hud.ac.uk
bDepartment of Pharmacy, University of Huddersfield, Queensgate, Huddersfield, HD1 3DH, UK
cDepartment of Chemistry, Faculty of Mathematics and Natural Sciences, Institut Teknologi Bandung, Jl. Ganesha No. 10, Bandung 40132, West Java, Indonesia
First published on 8th September 2025
In an attempt to react aminocyclopropenones with cyclic imines in order to synthesise amido-substituted pyrrolizidine natural products, we found that aminocyclopropenones undergo a previously unreported stereospecific and regiospecific catalyst-free, thermal ring-opening reaction with alcohols to yield β-enamino esters (also known as vinylogous carbamates or aminoacrylates). We report 21 examples in 45 to 97% isolated yield. The reaction occurs via nucleophilic attack at the cyclopropenone carbonyl followed by regiospecific ring opening of the cyclopropenone with retention of alkene geometry. Preliminary studies with colon cancer cell line HCT116 show that a sub-set of these β-enamino esters have promising activity.
Building upon the pioneering work of Eicher,1 our research group2–4 and those of Cui5 and Wood6 have shown that a variety of heterocycles such as pyrrolizidines3 and indolizidines2 (e.g., aza-sugar 4), pyrroloisoquinolines and indolizinoindoles (e.g., indoles 5)1,2,5 and the aspergilline A precursor 66 (Fig. 1) can be synthesised from the appropriate cyclic imine in this way. Other groups have used cyclopropenones in the synthesis of indolizinones, pyrroloisoquinolines and other fused systems by using dearomative cycloaddition to the carbon–nitrogen double bond of pyridines,7 isoquinolines7 and benzoxazoles,8 or via the in situ oxidation of tetrahydroisoquinolines with I2-DMSO.9
![]() | ||
| Fig. 1 Examples of fused pyrrolones accessed from cyclopropenones.2–6 | ||
One series of natural products that has attracted our attention is the amido-substituted pyrrolizidines (Fig. 2), a class of alkaloids that includes jenamidines A1/A27 (X = H) and B1/B28 (X = OH),2,3,10 NP25302 9,11,12 pyrrolizixenamides A–C 10,13 bohemamine D 11 and related natural products,14–18 and the legonmycins 1219,20 and the related fused azetidine natural products.21,22 The natural products 7–12 are unusual in that they represent pyrrolizidines that are of bacterial rather than plant origin.10–22 Compounds 10–12 show interesting activity against leukemic10,12 and non-small cell cancer cell lines.18
We anticipated that these amido-substituted pyrrolizidines might be accessed via the reaction of an amino-substituted cyclopropenone 14 with the appropriate cyclic imine (such as pyrroline 13, Scheme 2) and were particularly interested by the possibility that we would be able to simultaneously install the fused pyrrolidinone ring system and the bridgehead tertiary alcohol that are present in the natural products 8, 11 and 12 (see Fig. 2) as we had previously observed that oxidation at this bridgehead was facile, occurring spontaneously in air.2,3 Herein, we discuss the results of our initial attempts to investigate the approach that is summarised in Scheme 2, and describe how we found instead that the amino-substituted cyclopropenones 14 reacted by an alternative pathway to produce non-cyclic β-enamino esters 15 (Scheme 3) in high yields. β-Enamino esters are useful targets as they are attractive building blocks in synthetic chemistry23–28 with reactivity as electrophiles and nucleophiles, and have synthetic utility as precursors for the synthesis of several classes of important aromatic heterocycles such as pyridines and fused pyridines,23,24,26 pyrroles,24–26 indoles,24,26 quinolines,23,25,26 pyrazines, oxazoles and imidazoles,26 and saturated N-heterocycles containing additional O, N or S atoms.27 β-Enamino esters have also been used as nucleophilic partners in Mitsunobu reactions allowing N-substitution,27 have been used as substrates for addition–elimination reactions with other amines23,25 thus allowing access to other β-enamino esters, and are used as starting materials for the synthesis of biologically relevant β-amino acids.24,28
Our study started, as shown in Scheme 4, with the synthesis of the known (diisopropylamino)phenylcyclopropenone 1847 using the established36,44,48 protocol of Friedel–Crafts reaction between tetrachlorocyclopropene and benzene. Hydrolysis of the Friedel–Crafts product gave the stable and isolable hydroxy(phenyl)cyclopropenone 16.36 Chlorination of 16 with thionyl chloride gave the chlorinated intermediate 17 which was reacted immediately with diisopropylamine to give the desired product 18. We noted that failure to react intermediate 17 upon isolation resulted in its ready hydrolysis back to the hydroxycyclopropenone 16.
Pyrroline 13 (Scheme 5) was synthesised using procedures reported in our previous work.2,3 All attempts to react pyrroline 13 with aminocyclopropenone 18 to give the desired amino-substituted pyrrolizidine 19 were unsuccessful. However, when ethanol was used as the solvent, a single new product was observed by TLC analysis. Isolation and spectroscopic analysis of this product revealed it to be the previously unreported enamino ester 20a, formed as the isomer shown (see later for spectroscopic and other evidence).
It is known that 2,3-diaryl/dialkyl-substituted cyclopropenones 2 can be used as sources of alkenes in a variety of processes that involve attack at the cyclopropenone followed by ring opening.51–61 Several of these processes involve C–C bond formation using C–H or C–C activation in the presence of Ru/Pd/Ag catalysts and additives.51–54 More notably, other examples, shown in Scheme 6, involve heteroatom attack at the carbonyl of the cyclopropenone and the formation of esters and amides 21 after ring opening,55–58 again requiring the presence of metal (Ag, Cu, Pd) catalysts. The use of triphenylphosphine in a metal-free catalytic ring opening reaction of cyclopropenones is a useful variant that has attracted recent attention, and is considered to proceed via the ketenyl phosphorus ylid 22 shown in Scheme 6.59–64 Isolated examples of the catalyst-free addition of just two nucleophiles (hydroxide65 and methanol66) to the carbonyl of a single type of cyclopropenone (diphenylcyclopropenone) followed by ring opening to give acrylates under thermal conditions have been reported (also shown in Scheme 6). 2-Methoxy-3-phenylcyclopropen-1-one is also known to react with water at the carbonyl carbon and gives the ring-opened acrylic acid dervative.67 The trisubstituted alkene products of these processes have proved to be useful for the synthesis of quinolones,58 as substrates for the synthesis of much sought after tetra-substituted alkenes after in situ Pd-catalysed C–H arylation,59 and for elaboration into indenes,61 benzazepines and phenanthrenes.63
The examples of ring-opening shown in Scheme 6 all relate to aryl and alkyl-substituted cyclopropenones. In contrast, the literature on amino-substituted cyclopropenones contains only two examples of nucleophilic attack at the carbonyl followed by ring opening. Thus, as part of a study that focused upon the generation of ynamines by the photolytic decarbonylation of aminocyclopropenones, it was observed, as shown in Scheme 7, that the reaction of morpholinophenylcyclopropenone with methanol gave the methyl enamino ester, although no experimental detail was given.44 The same authors reported the use of N-(pentafluorophenyl)aminophenylcyclopropenone (also shown in Scheme 7) for the generation of ynamines by photolytic decarbonylation, and obtained the enamino ester after reaction in methanolic acetone overnight.45 With the prior work limited to just two aminocyclopropenones reacting with one alcohol (methanol) as a side reaction in studies focused upon photolytic decarbonylation, and also considering the importance of the enamino ester23–28 and alkene51–64 products, we thought it worthwhile to undertake a more detailed study focused upon the unexplored, facile, catalyst free, thermal process that we observed in Scheme 5.
We quickly found that the conversion of aminocyclopropenone 18 into the enamino ester 20a could be carried out by heating compound 18 in neat ethanol or with ethanol in various solvents as shown in Table 1. The best conditions were found to be a solution of 5 equivalents of ethanol in chloroform at 80 °C for 18 hours (100% conversion of compound 18 into product 20a was estimated by 1H NMR, with 84% isolated yield after purification by chromatography).
| Solvent | Equivalents of EtOH | Temp. (°C) | Time (h) | % Conversion for 18a to 20a (1H nmr)a |
|---|---|---|---|---|
| a Estimated by analysis of the crude reaction mass after the removal of the excess EtOH and reaction solvent. b The isolated yield (after purification by chromatography) fell by ∼20% when DMSO was used as solvent. | ||||
| Neat | 285 | 80 | 18 | 100 |
| CDCl3 | 100 | 80 | 18 | 100 |
| CDCl3 | 20 | 80 | 18 | 100 |
| CDCl3 | 10 | 80 | 18 | 100 |
| CDCl3 | 5 | 80 | 18 | 100 |
| CDCl3 | 4 | 80 | 18 | 99 |
| CDCl3 | 3 | 80 | 18 | 87 |
| CDCl3 | 2 | 80 | 18 | 73 |
| CDCl3 | 1 | 80 | 18 | 30 |
| CDCl3 | 5 | 70 | 18 | 68 |
| CDCl3 | 5 | 50 | 18 | 37 |
| CDCl3 | 5 | 20 | 18 | 5 |
| CDCl3 | 5 | 80 | 6 | 71 |
| CDCl3 | 5 | 80 | 1 | 11 |
| D6-DMSO | 5 | 80 | 18 | 100b |
| D3-MeCN | 5 | 80 | 18 | 80 |
The identity of compound 20a was inferred by analogy to the literature examples reported in Schemes 6 and 7, and by fully consistent mechanistic considerations and spectroscopic data, including 2D-NMR experiments. Thus, NOESY showed a strong correlation of the alkene CH with the methyl groups of the iso-propyl group, inferring that the alkene CH and NiPr2 were close, hence discounting attack of the alcohol at C1 followed by C1–C3 cleavage that would form alkene isomer i (see Scheme 8). NOESY also showed a correlation of the phenyl protons with the methyl and CH protons of the iso-propyl group, indicating (E)-isomer 20a had formed rather than alkene ii or the (Z)-isomer of 20a, hence leading to our assignment of (E)-isomer 20a as the product. In the HMBC, the C
O showed coupling to the CH2 of the OEt group, inferring that EtOH had attacked the C1 carbonyl of the cyclopropenone (black arrows and structures in Scheme 8), rather than undergoing conjugate addition to either C2 or C3 of the alkene (blue arrows and structures in Scheme 8). No evidence of aldehyde peaks was seen in 1D or 2D NMR spectra, hence discounting addition to either C2 or C3 of the alkene followed by ring opening. Together, these observations indicated to us that ring opening had occurred by the route suggested in Scheme 8, i.e. attack at C1 followed by C1–C2 cleavage, leading to the enamino ester 20a rather than following the alternative ring opening pathway (red arrows and structures on Scheme 8) or conjugate addition pathway (blue arrows and structures on Scheme 8). To help confirm our assignment, we produced a spectroscopically identical compound to enamino ester 20a using an independent synthetic route as shown in Scheme 9, thus discounting the possible formation of alkene regioisomers i and ii, as well as discounting the formation of any products that arise from reaction at the alkene group of the cyclopropenone. Reactions with other substrates (see later) produced two known alkenes with spectroscopic data identical to the literature. All of this evidence, together with literature precedent relating to the structure of the alkenes produced by the processes shown in Schemes 6 and 7 support the structural assignment, and strongly support the reaction pathway proposed in Scheme 8.
We next applied the optimised conditions (5 equivalents of alcohol in chloroform at 80 °C for 18 hours) to the reaction of a range of alcohols with aminocyclopropenone 18 as detailed in Table 2. The reaction worked with primary, secondary and tertiary alcohols, phenolic, benzylic, allylic and propargylic alcohols to give the enamino esters 20b–n with generally good to excellent isolated yields as shown in Table 2. All compounds gave spectroscopic data that was consistent with the assigned structures and were isolated in good purity as single isomers.‡ It was notable, and in keeping with similar diisopropylamino compounds reported in the literature,68 that the isopropyl group gave very weak, broad signals in the 13C NMR spectra recorded for these compounds, and that occasionally the isopropyl signals were not distinguishable from the baseline.
In order to test the reaction scope, we also investigated other nucleophiles and other aminocyclopropenones as shown in Table 3. Thus, amines (aliphatic, benzylic or aryl), valinol, water or dilute sodium hydroxide gave no isolable products with aminocyclopropenone 18, leading only to complex mixtures under our standard conditions. Other conditions and the use of deactivated nitrogen sources such as TsNH2 were not explored. Thiophenol reacted to give the thioester 20o. 2-Dibenzylamino-3-phenylcyclopropen-1-one 23,47,49 2-dimethylamino-3-phenylcyclopropen-1-one 2443 and 2-diisopropylamino-3-(2′,4′-dimethylphenyl)cyclopropen-1-one 2547,49 reacted with alcohols to give the enamino esters 20p–25v, showing that variations in the nature of the aryl and dialkylamino groups could be made. Alkenes 20p69 and 20s25,70–72 have been reported previously where each was synthesised by routes quite different to ours and different to each other. In each case, our compounds had 1H and 13C NMR spectra/data identical to those reported,69,70 justifying the regiochemical, stereochemical and mechanistic arguments presented above in Scheme 8. In the case of compound 20p, we observed, as per the identical published spectrum,69 that the signal for the methylene of the benzyl group was very weak and broad in the 13C NMR spectrum, and almost indistinguishable from the baseline. This phenomenon was observed with the other N-benzyl compounds shown in Table 3, and also occurred with the methine and methyl signals in the 13C NMR spectra of the NiPr2 compounds that appear in Table 3. In the case of known compound 20s, no literature spectrum was available, but the NMR data matched the published data.25,70,72 2-Diisopropylamino-3-(2′,4′-dimethoxyphenyl)cyclopropen-1-one 26 was found to be unreactive towards ethanol and methanol, indicating that strongly electron donating groups on the aryl substituent are not tolerated, possibly due to their ability to lower the reactivity of the cyclopropenone carbonyl by electron donation. The 2-amino-3-arylcyclopropenones 23–2643,47,49 used in Table 3 are known isolable compounds and were synthesised by adapting the route shown above in Scheme 4 to allow the use of substituted benzenes and other amines in the place of benzene and diisopropylamine. The synthesis of 2-dimethylamino-3-phenylcyclopropenone 24 required the use of dimethylaminotrimethylsilane rather than dimethylamine as the amine, a requirement also noted by other workers.43
| Entry | Ar | R | R1XH | % Yield 20 |
|---|---|---|---|---|
| a Contained a small amount of phenol: see experimental and footnote therein. | ||||
| — | Ph | iPr | Primary amine | No reaction |
| — | Ph | iPr | Secondary amine | No reaction |
| — | Ph | iPr | Valinol | No reaction |
| — | Ph | iPr | H2O | No reaction |
| — | Ph | iPr | NaOH | No reaction |
| 20o | Ph | iPr | PhSH | 71 |
| 20p | Ph | Bn | EtOH | 78 |
| 20q | Ph | Bn | PhOH | ∼60a |
| 20r | Ph | Bn |
|
82 |
| 20s | Ph | Me | MeOH | 89 |
| 20t | 2,4-Me2C6H4 | iPr | MeOH | 73 |
| 20u | 2,4-Me2C6H4 | iPr | EtOH | 92 |
| 20v | 2,4-Me2C6H4 | iPr | iPrOH | 54 |
| — | 2,4-(OMe)2C6H4 | iPr | EtOH/MeOH | No reaction |
In two final reactions, shown in Scheme 10, it was determined that the cyclopropenones 27 and 16, isolated as intermediates from the general aminocyclopropenone synthesis shown previously in Scheme 4, reacted with ethanol to give the alkenes 28 and 29, showing that other heteroatom-substituted cyclopropenones undergo reaction in the same way as aminocyclopropenones. The stable and known49 intermediate 2-chloro-3-(2′,4′-dimethoxyphenyl)cyclopropenone 27 used in this reaction was isolated after the hydrolysis of the intermediate Friedel–Crafts product (Scheme 4) obtained from 1,3-dimethoxybenzene. The stability of this material was in contrast to that of 2-chloro-3-(phenyl)cyclopropenone 17 and this can be attributed to the ability of the electron donating methoxy groups to lower the reactivity of the cyclopropenone ring. Alkene 29 has been reported previously, is tautomeric with the thermodynamically less stable aldehyde and is known exist as the (Z)-isomer.73,74 It is the same compound used in Scheme 9 and was identical to that material. The stereochemistry of the previously unreported chloroalkene 28 could not be determined, but the compound was a single stereoisomer. We are investigating the applications of these types of cyclopropenones and their alkene products further.
Mishiro and Kunishima found that 2-dialkylamino-3-(aryl)-cyclopropen-1-ones were strong inhibitors of the growth of HCT116 colon cancer cells.50 We carried out preliminary studies with colon cancer cell line HCT116 in order to establish IC50 values for the aminocyclopropenone 18 and four of the enamino esters derived from it. We thought this would be of interest as this previous study50 had compared 2-dialkylamino-3-(aryl)-cyclopropen-1-ones to simple amide analogues [ArC(O)NR2], concluding that the cyclopropenone ring was essential for activity. Our results are shown in Table 4. Compounds 18, 20a, 20f, 20h and 20j were screened against colon cancer cell line HCT116 with cis-platin as a control.
| Compound | IC50 (μmol) for inhibition of HCT116 growth |
|---|---|
| 18 | 117 ± 53 |
| 20a | 23.7 ± 19 |
| 20f | 33 ± 14 |
| 20h | 72 ± 10 |
| 20j | 13.9 ± 9 |
| cis-platin | 1.03 ± 0.36 |
As shown in Table 4, the 2-dialkylamino-3-phenyl-cyclopropen-1-one 18 showed the weakest cytotoxic activity and appeared not to be as potent as noted previously for other compounds in this class.50 It can also be seen from the results in Table 4 that the four enamino ester compounds showed micromolar cytotoxic activity that was more potent than that of compound 18, indicating that these enamino esters may warrant further biological evaluation. The possibility that the two classes of compounds form the same biological conjugate (shown as structure 30 in Scheme 11) is worthy of consideration given that they have similar electrophilic properties and H-bond acceptor capacity, and that a similar mode of reactivity has been noted previously with aryl/alkyl-substituted cyclopropenones.37,41 We intend to study the biological activity of these enamino esters in more detail.
Although all but two of the β-enamino ester series 20a–v that we have produced in this work are unreported, it is noteworthy that other non-cyclic β-enamino esters (also known as vinylogous carbamates or aminoacrylates), albeit produced by different pathways to the one we report, are a well-known and versatile class of compound. The most common route for the synthesis of β-enamino esters is the reaction of a 1,3-dicarbonyl with an amine (as used in the confirmatory synthesis shown in Scheme 9).24,74–77 This requires the synthesis of the appropriate 1,3-dicarbonyls via reaction of an ester with an excess of alkyl formate in the presence of sodium hydride, and is generally utilised with only simple commercially available esters, so that an additional step is required for non-simple esters, resulting in a 3-step synthesis.74,76,77 The process often gives rise to (E)/(Z) mixtures, although hindered amines tend to give the (E)-alkene. Our route is a simple process reacting alcohols with easily accessible amino-substituted cyclopropenones (two steps from commercially available materials), allows variation of the aryl and amine substituents on the aminocyclopropenone ring, gives good to high yields with a wide variety of readily available alcohols, and allows access to a range of previously unreported β-enamino esters in a regio- and stereoselective manner. The other commonly used route for the synthesis of β-enamino esters is the reaction of dimethylformamide-dimethyl acetal (DMF-DMA)23,25,70,71,78 with active methylene compounds, a route that is restricted to dimethylamino-substituted β-enamino esters. Other dialkylformamide acetal derivatives are rarely used as they are not commercially available and require synthesis. This route also requires the synthesis of any non-simple esters that are used as the active methylene compounds. The DMF-DMA process also tends to use DMF as solvent at high temperature with long reaction times. Less common and less general routes for the synthesis of β-enamino esters include the rhodium catalysed decomposition of diazoketamines,27,28 the copper-catalysed coupling of thioamides to diazocarbonyls,72 the synthesis of diesters by reaction of dialkyl acetylenedicarboxylates with anilines,79 nickel catalysed cross-couplings of organoboronic acids with isoxazoles,80 and the reaction of disubstituted β-enamino esters with bromodifluoroacetates to give α-keto ester substituted derivatives.81 The route that we report is an important contribution to a greater understanding of the reactivity of aminocyclopropenones, and offers a convenient and useful addition to the methods that are available for the synthesis of β-enamino esters, a class of molecule with high synthetic utility.
2-(Dialkylamino)-3-arylcyclopropen-1-ones 18 and 23–26 are known and were synthesised by adapting the published routes43,47,49 as described below. The intermediate 2-hydroxy- and 2-chloro-3-aryl-cyclopropenones 16 and 27 are also known36,49 and were synthesised by adapting the published routes as described below. The enamino esters 20p69 and 20s25,70,71 have been reported previously each using a different route to that which we report. Enamino esters 20a–o, 20q, 20r, 20t–v and alkene 28 are unreported. Cyclic imine 13 was prepared as previously described.2,3 Compound 29 has been reported previously.73,74 Copies of the 1H and 13C NMR spectra for previously unreported compounds are available as SI.
:
EtOAc 7
:
3 to 2
:
3) to afford the title compound as a pale brown oil (595 mg, 2.59 mmol, 46%), solidifying to a pale yellow solid, m.p.: 130–132 °C. Known compound, m.p. not previously reported.36,471H NMR (CDCl3, 400 MHz) δH 7.59–7.57 (m, 2H, 2 × ArH), 7.43–7.39 (m, 2H, 2 × ArH), 7.36–7.32 (m, 1H, ArH), 4.20 (septet, 1H, J = 6.8 Hz, NCH), 3.64 (septet, 1H, J = 6.6 Hz, NCH), 1.40 (dd, 6H, J = 6.8 Hz, N–CHC2H6), 1.39 (dd, 6H, J = 6.6 Hz, N–CHC2H6). 13C NMR (CDCl3, 100 MHz) δC 146.6 (qC), 140.8 (qC), 129.0 (CH), 128.9 (CH), 128.9 (CH), 125.1 (qC), 110.1 (qC), 54.9 (NCH), 47.9 (NCH), 23.6 (CH3), 21.3 (CH3). NMR data consistent with that reported previously.36,47
CH), 7.32–7.25 (m, 2H, 2 × ArH), 7.23–7.20 (m, 3H, 3 × ArH), 4.12 (q, J = 7.1 Hz, 2H, OCH2CH3), 3.49 (septet, J = 6.6 Hz, 2H, 2 × NCHC2H6), 1.19 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.08 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 170.39 (qC), 143.25 (CH), 138.42 (qC), 131.16 (CH), 127.78 (CH), 126.25 (CH), 98.24 (qC), 59.39 (OCH2), 47.17 (broad, NCH), 21.74 (broad, CH3), 14.65 (CH3). IR νmax (thin film, cm−1): 2976, 1734, 1676, 1571, 1495, 1459, 1369, 1298, 1246, 1180. m/z (ESI+) calculated for C17H26NO2 [M + H]+; 276.1958, observed 276.1961.
CH), 7.31–7.26 (m, 2H, 2 × ArH), 7.24–7.18 (m, 3H, 3 × ArH), 3.61 (s, 3H, OCH3), 3.47 (septet, J = 6.6 Hz, 2H, 2 × NCHC2H6), 1.06 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 170.89 (qC), 143.52 (CH), 138.31 (qC), 131.15 (CH), 127.91 (CH), 126.43 (CH), 97.84 (qC), 51.18 (OCH3), 47.20 (broad, NCH), 21.68 (broad, CH3). IR νmax (thin film, cm−1): 2971, 1675, 1590, 1496, 1465, 1455, 1433, 1370, 1308, 1260, 1190. m/z (ESI+) calculated for C16H24NO2 [M + H]+; 262.1802, observed 262.1802.
CH), 7.29–7.25 (m, 2H, 2 × ArH), 7.21–7.17 (m, 3H, 3 × ArH), 4.99 (septet, J = 6.2 Hz, 1H, OCH(CH3)2), 3.47 (septet, J = 6.7 Hz, 2H, 2 × NCHC2H6), 1.15 (d, J = 6.2 Hz, 6H, OCH(CH3)2), 1.06 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 169.94 (qC), 142.98 (CH), 138.52 (qC), 131.16 (CH), 127.64 (CH), 126.06 (CH), 98.66 (qC), 66.22 (OCH), 47.21 (weak, broad, NCH), 22.15 (CH3), 21.76 (weak, broad, CH3). IR νmax (thin film, cm−1): 2980, 2932, 2874, 1731, 1666, 1593, 1495, 1465, 1432, 1371, 1336, 1299. m/z (ESI+) calculated for C18H28NO2 [M + H]+; 290.2115, observed 290.2116.
CH), 7.27–7.24 (m, 2H, 2 × ArH), 7.19–7.16 (m, 3H, 3 × ArH), 3.47 (septet, J = 6.6 Hz, 2H, 2 × NCHC2H6), 1.39 (s, 9H, OC4H9), 1.06 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 169.96 (qC), 142.46 (CH), 138.88 (qC), 131.10 (CH), 127.58 (CH), 125.89 (CH), 99.80 (qC), 78.22 (qC), 47.00 (weak, broad, NCH), 28.52 (CH3), 21.87 (weak, broad, CH3). IR νmax (thin film, cm−1): 2976, 1683, 1597, 1576, 1460, 1369, 1297, 1248, 1216, 1179, 1145. m/z (ESI+) calculated for C19H30NO2 [M + H]+; 304.2271, observed 304.2270.
CH), 7.29–7.25 (m, 2H, 2 × ArH), 7.22–7.17 (m, 3H, 3 × ArH), 4.04 (t, J = 6.6 Hz, 2H, OCH2CH2), 3.49 (septet, J = 6.7 Hz, 2H, 2 × NCHC2H6), 1.52 (m, 2H, CH2), 1.28 (m, 2H, CH2), 1.06 (br. s, 12H, 2 × NCHC2H6), 0.86 (t, J = 7.4 Hz, 3H, CH3). 13C NMR (CDCl3, 100 MHz) δC 170.46 (qC), 143.14 (CH), 138.43 (qC), 131.15 (CH), 127.73 (CH), 126.21 (CH), 98.27 (qC), 63.30 (OCH2), 47.11 (weak, broad, NCH), 31.02 (CH2), 21.94 (weak, broad, CH3), 19.25 (CH2), 13.76 (CH3). IR νmax (thin film, cm−1) 2935, 1734, 1689, 1660, 1599, 1252, 1215, 1176, 1148. m/z (ESI+) calculated for C19H30NO2 [M + H]+; 304.2271, observed 304.2270.
CH), 7.33–7.26 (m, 2H, 2 × ArH), 7.24–7.22 (m, 3H, 3 × ArH), 4.31 (t, J = 6.0 Hz, 2H, OCH2), 3.65 (t, J = 6.0 Hz, 2H, CH2Cl), 3.53 (septet, J = 6.6 Hz, 2H, 2 × NCHC2H6), 1.09 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 169.60 (qC), 143.97 (CH), 137.92 (qC), 131.16 (CH), 127.88 (CH), 126.46 (CH), 97.42 (qC), 63.07 (OCH2), 42.34 (CH2Cl). IR νmax (thin film, cm−1): 2934, 1667, 1589, 1450, 1301, 1261. m/z (ESI+) calculated for C17H24NClO2Na [M + Na]+; 332.1388, observed 332.1395.
CH), 7.31–7.23 (m, 2H, 2 × ArH), 7.23–7.20 (m, 3H, 3 × ArH), 5.92–5.83 (m, 1H, CH
CH2), 5.14–5.05 (m, 2H, CH
CH2), 4.57–4.55 (m, 2H, CH2), 3.49 (septet, J = 6.6 Hz, 2H, 2 × NCHC2H6), 1.06 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 169.96 (qC), 143.57 (CH), 138.26 (qC), 133.71 (CH), 131.19 (CH), 127.85 (CH), 126.36 (CH), 115.79 (CH2), 97.87 (qC), 63.99 (CH2), 47.15 (weak, broad, NCH), 21.87 (weak, broad, CH3). IR νmax (thin film, cm−1): 2975, 1683, 1596, 1574, 1497, 1432, 1370, 1300, 1249, 1215, 1180, 1143. m/z (ESI+) calculated for C18H26NO2 [M + H]+; 288.1958, observed 288.1958.
CH), 7.34–7.27 (m, 2H, 2 × ArH), 7.25–7.22 (m, 3H, 3 × ArH), 4.66 (d, J = 2.4 Hz, 2H, CH2), 3.51 (septet, J = 6.6 Hz, 2H, 2 × NCHC2H6), 2.37 (t, J = 2.4 Hz, 1H, C
CH), 1.09 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 169.33 (qC), 144.27 (CH), 137.83 (qC), 131.20 (CH), 127.93 (CH), 126.51 (CH), 97.26 (qC), 79.59 (qC), 73.23 (CH), 51.02 (CH2), 47.35 (very weak, broad, NCH), 21.88 (very weak, broad, CH3). IR νmax (thin film, cm−1): 3295, 2979, 1673, 1563, 1456, 1367, 1244, 1178, 1070. m/z (ESI+) calculated for C18H24NO2 [M + H]+; 286.1802, observed 286.1802.
CH), 7.31–7.26 (m, 2H, 2 × ArH), 7.23–7.20 (m, 3H, 3 × ArH), 7.12 (dd, J = 8.2 Hz, 5.4 Hz, 4H, 2 × ArH), 7.08 (dd, J = 8.2 Hz, 5.4 Hz, 4H, 2 × ArH), 5.08 (s, 2H, CH2), 3.49 (septet, J = 6.6 Hz, 2H, 2 × NCHC2H6), 2.31 (s, 3H, CH3), 1.05 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 170.06 (qC), 143.57 (CH), 138.31 (qC), 136.80 (qC), 134.94 (qC), 131.22 (CH), 128.87 (CH), 127.84 (CH), 127.19 (CH), 126.34 (CH), 97.99 (qC), 64.89 (CH2), 47.23 (weak, broad, NCH), 22.02 (weak, broad, CH3), 21.14 (CH3). IR νmax (thin film, cm−1): 2976, 1733, 1687, 1596, 1548, 1450, 1379, 1265, 1194, 1173. m/z (ESI+) calculated for C23H30NO2 [M + H]+; 352.2271, observed 352.2271.
CH), 7.33–7.29 (m, 2H, 2 × ArH), 7.25–7.18 (m, 5H, 5 × ArH), 6.84 (d, J = 8.6 Hz, 2H, 2 × ArH), 5.07 (s, 2H, CH2), 3.81 (s, 3H, OCH3), 3.51 (septet, J = 6.6 Hz, 2H, 2 × NCHC2H6), 1.07 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 170.07 (qC), 158.86 (qC), 143.54 (CH), 138.32 (qC), 131.20 (CH), 130.14 (qC), 128.83 (CH), 127.83 (CH), 126.33 (qC), 113.59 (CH), 90.03 (qC), 64.73 (OCH2), 55.24 (1C, OCH3), 22.1 (weak, broad, CH3). IR νmax (thin film, cm−1): 2980, 1665, 1589, 1516, 1464, 1439, 1371, 1307, 1246, 1173, 1142, 1028. m/z (ESI+) calculated for C23H30NO3 [M + H]+; 368.2220, observed 368.2235.
CH), 7.31–7.26 (m, 3H, 2 × ArH), 7.24–7.21 (m, 2H, 2 × ArH), 7.19 (d, 1H, J = 8.0 Hz, ArH), 6.79 (d, 1H, J = 7.6 Hz, ArH), 6.75 (dd, 1H, J = 8.2 Hz, 2.4 Hz, ArH), 6.70 (s, 1H, ArH), 5.10 (s, 2H, CH2), 3.71 (s, 3H, OCH3), 3.50 (septet, J = 6.6 Hz, 2H, 2 × NCHC2H6), 1.06 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 170.03 (qC), 159.57 (qC) 143.25 (CH), 139.52 (qC), 138.32 (qC), 131.26 (CH), 129.17 (CH), 127.89 (CH), 126.40 (CH), 119.00 (CH), 113.31 (CH), 111.58 (CH), 97.82 (qC), 64.74 (CH2), 55.17 (OCH3), 47.35 (weak, broad, NCH), 21.83 (weak, broad, CH3). IR νmax (thin film, cm−1): 2940, 1738, 1690, 1597, 1461, 1270, 1195, 1175. m/z (ESI+) calculated for C23H30NO3 [M + H]+; 368.2220, observed 368.2220.
CH), 7.33–7.28 (m, 1H, ArH), 7.26–7.19 (m, 3H, 3 × ArH), 7.15 (dd, J = 7.4 Hz, 1.2 Hz, 1H, ArH), 7.10 (ddd, J = 8.0 Hz, 1.5 Hz, 1.5 Hz, 1H, ArH), 6.70 (ddd, J = 7.4 Hz, 1.0 Hz, 1.0 Hz, 1H, ArH), 6.62 (dd, J = 8.0 Hz, 0.6 Hz, 1H, ArH), 5.09 (s, 2H, CH2), 3.87 (br. s, 2H, NH2), 3.51 (septet, J = 6.5 Hz, 2H, 2 × NCHC2H6), 1.07 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 170.02 (qC), 146.32 (qC), 143.80 (CH), 138.34 (qC), 131.14 (CH), 130.66 (CH), 129.15 (CH), 128.00 (CH), 126.49 (CH), 122.01 (qC), 117.93 (CH), 115.89 (CH), 97.57 (qC), 67.79 (OCH2), 47.25 (broad, NCH), 21.71 (broad, CH3). IR νmax (thin film, cm−1): 2976, 1734, 1676, 1571, 1495, 1459, 1369, 1298, 1246, 1180. m/z (ESI+) calculated for C22H29N2O2 [M + H]+; 353.2224, observed 353.2221.
CH), 7.32–7.21 (m, 6H, 6 × ArH), 7.11 (dd, J = 7.9 Hz, 7.9 Hz, 2H, ArH), 7.03 (ddd, J = 7.5 Hz, 0.9 Hz, 0.9 Hz, 1H, ArH), 5.07 (s, 2H, CH2), 3.51 (septet, J = 6.5 Hz, 2H, 2 × NCHC2H6), 1.06 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 169.87 (qC), 143.74 (CH), 138.23 (qC), 137.32 (qC), 131.22 (CH), 129.25 (qC), 128.55 (CH), 128.39 (CH), 127.88 (CH), 126.43 (CH), 124.63 (CH), 117.80 (CH), 97.75 (qC), 60.72 (OCH2), 47.30 (weak, broad, NCH), 22.00 (broad, CH3). IR νmax (thin film, cm−1): 2851, 2126, 1731, 1681, 1594, 1492, 1450, 1379. m/z (ESI+) calculated for C22H27N4O2 [M + H]+; 379.2129, observed 379.2129.
CH), 7.32–7.22 (m, 7H, 7 × ArH), 7.11 (t, J = 7.4 Hz, 1H, 1 × ArH), 7.05 (d, 2H, J = 7.6 Hz, 2 × ArH), 3.58 (bs, 2H, 2 × NCHC2H6), 1.12 (bs, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 169.05 (qC), 152.12 (qC), 144.90 (CH), 137.88 (qC), 131.24 (CH), 128.88 (CH), 127.98 (CH), 126.59 (CH), 124.56 (CH), 122.16 (CH), 97.11 (qC). IR νmax (thin film, cm−1): 3378, 2980, 1666, 1590, 1557, 1485, 1456, 1261, 1194, 1140. m/z (ESI+) calculated for C21H25NO2Na [M + Na]+; 346.1778, observed 346.1785.
CH), 7.41–7.37 (m, 7H, 7 × ArH), 7.35–7.29 (m, 3H, 3 × ArH), 3.52 (bs, 2H, 2 × NCHC2H6), 1.05 (bs, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 188.54 (qC), 142.02 (CH), 137.04 (qC), 135.26 (CH), 132.84 (CH), 131.08 (qC), 128.55 (CH), 128.28 (CH), 128.24 (CH), 127.95 (CH), 107.01 (qC), 48.94 (very weak, very broad, NCH), 20.60 (very weak, very broad, CH3). IR νmax (thin film, cm−1): 2976, 1651, 1549, 1477, 1457, 1386, 1305, 1219, 1110. m/z (ESI+) calculated for C21H26NOS [M + H]+; 340.1735, observed 340.1738.
CH), 7.33–7.25 (m, 6H, 6 × ArH), 7.16–7.06 (m, 9H, 9 × ArH), 4.14 (q, J = 7.1 Hz, 2H, OCH2CH3), 4.04 (bs, 4H, 2 × NCH2C6H5), 1.18 (t, J = 7.1 Hz, 3H, OCH2CH3). 13C NMR (CDCl3, 100 MHz) δC 170.27 (qC), 148.75 (CH), 136.78 (qC), 136.14 (qC), 131.59 (CH), 128.65 (CH), 127.63 (CH), 127.57 (CH), 127.46 (CH), 126.54 (CH), 100.70 (qC), 59.79 (OCH2), 55.10 (very weak, broad, NCH2), 14.59 (CH3). IR νmax (thin film, cm−1): 2989, 1684, 1593, 1389, 1275, 1200, 1140, 1133. m/z (ESI+) calculated for C25H26NO2 [M + H]+; 372.1958, observed 372.1958. Previously reported by other workers using a different route.69 NMR data is consistent with that reported for this compound previously.69
CH), 7.35–7.27 (m, 8H, 8 × ArH), 7.25–7.17 (m, 3H, 3 × ArH), 7.16–7.14 (m, 3H, 3 × ArH), 7.12–7.06 (m, 6H, 6 × ArH), 4.04 (br. s, 4H, 2 × NCH2C6H5); phenol was seen as small triplet and doublet just below 7 ppm with the OH at ∼5.3 ppm (∼20%). 13C NMR (CDCl3, 100 MHz) δC 168.99 (qC), 155.76 (qC, PhOH), 151.84 (qC), 150.24 (CH), 136.38 (qC), 135.63 (qC), 131.69 (CH), 129.59 (CH, PhOH), 129.05 (CH), 128.75 (CH), 127.84 (CH), 127.75 (CH), 127.49 (CH), 126.88 (CH), 124.88 (CH), 122.07 (CH), 120.50 (CH, PhOH), 115.32 (CH, PhOH), 99.51 (qC). IR νmax (thin film, cm−1): 2976, 1734, 1676, 1571, 1495, 1459, 1369, 1298, 1246, 1180. m/z (ESI+) calculated for C29H26NO2 [M + H]+; 420.1958, observed 420.1967.
CH), 7.33–7.27 (m, 7H, 7 × ArH), 7.17–7.11 (m, 7H, 7 × ArH), 7.08–7.02 (m, 5H, 5 × ArH), 5.11 (s, 2H, CH2), 4.06 (bs, 4H, 2 × NCH2C6H5). 13C NMR (CDCl3, 100 MHz) δC 169.84 (qC), 149.12 (CH), 137.51 (qC), 136.60 (qC), 135.94 (qC), 131.63 (CH), 128.78 (qC), 128.67 (CH), 128.59 (CH), 127.69 (CH), 127.62 (CH), 127.45 (CH), 126.69 (CH), 124.66 (CH), 117.86 (CH), 100.17 (qC), 61.09 (OCH2). IR νmax (thin film, cm−1): 2973, 2125, 1684, 1593, 1494, 1453, 1377, 1295, 1229, 1129. m/z (ESI+) calculated for C30H27N4O2 [M + H]+; 475.2129, observed 475.2135.
CH), 7.30–7.24 (m, 2H, 2 × ArH), 7.23–7.17 (m, 3H, 3 × ArH), 3.62 (s, 3H, OCH3), 2.66 (s, 6H, N(CH3)2). 13C NMR (CDCl3, 100 MHz) δC 170.62 (qC), 149.29 (CH), 136.54 (qC), 132.11 (CH), 127.35 (CH), 126.26 (CH), 98.97 (qC), 51.16 (CH3), 43.02 (CH3). Previously reported by other workers using a different route.25,70,71 NMR data is consistent with that reported previously and was identical to a sample produced using the reported route.
CH), 6.99–6.91 (m, 3H, 3 × ArH), 3.60 (s, 3H, OCH3), 3.45 (septet, J = 6.6 Hz, 2H, 2 × NCHC2H6), 2.31 (s, 3H, ArCH3), 2.15 (s, 3H, ArCH3), 1.06 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 170.98 (qC), 143.45 (CH), 137.82 (qC), 136.38 (qC), 134.29 (qC), 131.11 (CH), 130.34 (CH), 126.29 (CH), 96.28 (qC), 51.15 (OCH3), 46.97 (very weak, broad, NCH), 22.70 (weak, very broad, N(CH(CH3)2)2), 21.24 (CH3), 20.01 (CH3). IR νmax (thin film, cm−1): 2974, 1664, 1581, 1486, 1477, 1442, 1431, 1308, 1283, 1195. m/z (ESI+) calculated for C18H28NO2 [M + H]+; 290.2115, observed 290.2126.
CH), 6.98–6.90 (m, 3H, 3 × ArH), 4.19–4.11 (m, 1H, OCH2CH3), 4.06–3.98 (m, 1H, OCH2CH3), 3.44 (septet, J = 6.7 Hz, 2H, 2 × NCHC2H6), 2.30 (s, 3H, ArCH3), 2.15 (s, 3H, ArCH3), 1.15 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.05 (br. s, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 100 MHz) δC 170.41 (qC), 143.19 (CH), 137.77 (qC), 136.18 (qC), 134.44 (qC), 131.09 (CH), 130.23 (CH), 126.18 (CH), 96.72 (qC), 59.21 (OCH2), 46.92 (very weak, broad, NCH), 22.05 (weak, broad, CH3), 21.23 (CH3), 20.00 (CH3), 14.73 (CH3). IR νmax (thin film, cm−1): 2975, 1673, 1569, 1503, 1454, 1369, 1245, 1184, 1163, 1142, 1114, 1046. m/z (ESI+) calculated for C19H30NO2 [M + H]+; 304.2271, observed 304.2268.
CH), 6.96–6.88 (m, 3H, 3 × ArH), 4.98 (septet, J = 6.2 Hz, 1H, OCH), 3.45 (septet, J = 6.7 Hz, 2H, 2 × NCHC2H6), 2.30 (s, 3H, ArCH3), 2.14 (s, 3H, ArCH3), 1.13 (d, J = 6.2 Hz, 3H, OCHCH3), 1.11 (d, J = 6.2 Hz, 3H, OCHCH3), 1.05 (bs, 12H, 2 × NCHC2H6). 13C NMR (CDCl3, 150 MHz) δC 170.00 (qC), 142.85 (CH), 137.71 (qC), 135.93 (qC), 134.58 (qC), 131.07 (CH), 130.07 (CH), 126.04 (CH), 97.21 (qC), 65.93 (OCH), 46.62 (very weak, broad, NCH), 22.16 (CH3), 22.07 (CH3), 21.71 (very weak, CH3), 21.21 (CH3), 19.99 (CH3). IR νmax (thin film, cm−1): 2974, 1666, 1592, 1464, 1434, 1369, 1304, 1258, 1174, 1143, 1108, 1086. m/z (ESI+) calculated for C20H32NO2 [M + H]+; 318.2428, observed 318.2441.
CH), 4.06 (q, 2H, J = 7.1 Hz, OCH2CH3), 3.85 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 1.15 (t, 3H, J = 7.1 Hz, OCH2CH3). 13C NMR (CDCl3, 100 MHz) δC 163.94 (qC), 162.16 (qC), 157.29 (qC), 146.35 (qC), 130.58 (CH), 121.44 (CH), 119.05 (qC), 104.42 (CH), 98.51 (CH), 60.26 (OCH2), 55.65 (OCH3), 55.41 (OCH3), 14.02 (CH3). IR νmax (thin film, cm−1): 2938, 2839, 1721, 1602, 1576, 1503, 1456, 1438, 1416, 1303, 1282, 1261, 1208. m/z (ESI+) calculated for C13H16ClO4 [M + H]+; 271.0732, observed 271.0732.
Footnotes |
| † Current address: Department of Chemistry and Applied Biosciences, ETH Zürich, Vladimir-Prelog-Weg 1-5/10, 8093 Zürich, Switzerland. |
| ‡ The NMR spectra for compounds 20d and 20k contain ∼10% of an unidentified common aliphatic contaminant that was present in the batch of CDCl3 used to collect NMR data for these samples after purification. The compounds could not subsequently be separated from this impurity. |
| § This material could not be completely separated from the excess of phenol used despite repeated attempts. The yield is estimated from the total amount of material obtained and the ratio of phenol to compound 20q in the proton NMR. |
| This journal is © The Royal Society of Chemistry 2025 |